AnHeart Therapeutics
Dr. Junyuan (Jerry) Wang is Chief Executive Officer & Co-Founder at AnHeart Therapeutics. He has more than 20 years of leadership experience in global clinical development and medical research, having previously worked at Merck Serono, BMS, Wyeth/Pfizer, The Medicines Company, and Merck & Co. He has broad drug development experience across multiple therapeutic areas including oncology, cardiovascular, neuroscience, and immunology. He has made key contributions to the successful NDA of Bosulif and Eliquis, and the latter became a multi-billion blockbuster drug. He has extensive experience with global health authorities including FDA, EMA, PMDA, and NMPA. He also served in leadership roles for professional societies and on the programming committee of leading scientific conferences. Dr. Wang earned his B.S. from the University of Science and Technology of China and his Ph.D. in Statistics from the Iowa State of University.
This person is not in any offices
AnHeart Therapeutics
AnHeart Therapeutics (“AnHeart”) is a clinical-stage global biopharmaceutical company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a potential best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for ROS1 TKI-naïve and TKI-pretreated patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC). Taletrectinib has received Breakthrough Therapy Designation (BTD) from both the US FDA and China NMPA for the treatment of patients with advanced or metastatic ROS1+ NSCLC, who are either ROS1 TKI treatment naïve or previously treated with crizotinib. The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors. The Company operates from offices in the US and China.